Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8786 results

  1. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Bictegravir–lenacapavir for treating HIV-1 [ID6744]

    Awaiting development Reference number: GID-TA11970 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Technologies for the detection of Hepatocellular Carcinoma

    Awaiting development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]

    Awaiting development Reference number: GID-TA11194 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation